Changeflow GovPing Pharma & Drug Safety ClinicalTrials.gov Study NCT07496645: Transcran...
Routine Notice Added Final

ClinicalTrials.gov Study NCT07496645: Transcranial Direct Current Stimulation for Aphasia

Favicon for clinicaltrials.gov ClinicalTrials.gov
Detected March 28th, 2026
Email

Summary

ClinicalTrials.gov has registered a new study, NCT07496645, investigating the use of transcranial direct current stimulation for aphasia. This registration provides public information about the study's design, objectives, and participating sites.

What changed

ClinicalTrials.gov has added a new study registration, NCT07496645, detailing research into transcranial direct current stimulation (tDCS) as a treatment for aphasia. The registration includes information on the study's purpose, methodology, eligibility criteria, and locations where the research is being conducted.

This entry serves as an informational notice for researchers, healthcare providers, and potential participants. It does not impose new regulatory requirements but makes information about this specific clinical trial publicly accessible. Compliance officers in healthcare or research settings should note this as a publicly available study, but no immediate action is required based solely on this registration.

Source document (simplified)

Show glossary

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
ClinicalTrials.gov
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07496645

Who this affects

Applies to
Healthcare providers Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical Trial Reporting
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Medical Research Neurology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ClinicalTrials.gov publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.